Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 11, 2016 - Issue 1
Submit an article Journal homepage
3,263
Views
64
CrossRef citations to date
0
Altmetric
Reviews

Targeting intrinsically disordered proteins in rational drug discovery

Susmitha AmbadipudiGerman Center for Neurodegenerative Diseases (DZNE), 37077Göttingen, GermanyORCID Iconhttps://orcid.org/0000-0002-6232-4233
ORCID Icon &
Markus ZweckstetterGerman Center for Neurodegenerative Diseases (DZNE), 37077Göttingen, Germany;Department for NMR-based Structural Biology, Max Planck Institute for Biophysical Chemistry, 37077Göttingen, Germany;DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Göttingen, 37073Göttingen, GermanyCorrespondence[email protected]
Pages 65-77 | Published online: 07 Nov 2015

Bibliography

••A comprehensive overview of multifunctional roles of IDPs.

  • Rezaei-Ghaleh N, Blackledge M, Zweckstetter M. Intrinsically disordered proteins: from sequence and conformational properties toward drug discovery. Chembiochem. 2012;13(7):930–950.

••Detailed review on experimental and computational methods for IDP characterization.

  • Jensen MR, Zweckstetter M, Huang JR, et al. Exploring free-energy landscapes of intrinsically disordered proteins at atomic resolution using NMR spectroscopy. Chem Rev. 2014;114(13):6632–6660.

•Comprehensive review on NMR and experimental techniques for IDP characterization.

••Atomic level study of the phosphorylation induced folding of an IDP.

  • Linding R, Jensen LJ, Diella F, et al. Protein disorder prediction: implications for structural proteomics. Structure. 2003;11(11):1453–1459.
  • Ward JJ, Sodhi JS, McGuffin LJ, et al. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol. 2004;337(3):635–645.
  • Pancsa R, Tompa P. Structural disorder in eukaryotes. PloS One. 2012;7(4):e34687.
  • Theillet FX, Binolfi A, Frembgen-Kesner T, et al. Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev. 2014;114(13):6661–6714.
  • Uversky VN, Dave V, Iakoucheva LM, et al. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev. 2014;114(13):6844–6879.

•Systematic review on IDPs and their connection to disease.

  • Oldfield CJ, Cheng Y, Cortese MS, et al. Comparing and combining predictors of mostly disordered proteins. Biochemistry. 2005;44(6):1989–2000.
  • Lobanov MY, Galzitskaya OV. How common is disorder? Occurrence of disordered residues in four domains of life. Int J Mol Sci. 2015;16(8):19490–19507.
  • Prilusky J, Felder CE, Zeev-Ben-Mordehai T, et al. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics. 2005;21(16):3435–3438.
  • Uversky VN, Oldfield CJ, Dunker AK. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys. 2008;37:215–246.
  • Sickmeier M, Hamilton JA, LeGall T, et al. DisProt: the database of disordered proteins. Nucleic Acids Res. 2007;35(Database issue):D786–93.
  • Varadi M, Kosol S, Lebrun P, et al. pE-DB: a database of structural ensembles of intrinsically disordered and of unfolded proteins. Nucleic Acids Res. 2014;42(Database issue):D326–35.
  • Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314(5800):777–781.
  • Romero PR, Zaidi S, Fang YY, et al. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. P Natl Acad Sci USA. 2006;103(22):8390–8395.
  • Hegyi H, Buday L, Tompa P. Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. PLoS Comput Biol. 2009;5(10):e1000552.
  • Markiv A, Rambaruth ND, Dwek MV. Beyond the genome and proteome: targeting protein modifications in cancer. Curr Opin Pharmacol. 2012;12(4):408–413.
  • Peng Z, Mizianty MJ, Xue B, et al. More than just tails: intrinsic disorder in histone proteins. Mol Biosyst. 2012;8(7):1886–1901.
  • Weatheritt RJ, Gibson TJ. Linear motifs: lost in (pre)translation. Trends Biochem Sci. 2012;37(8):333–341.
  • Babu MM, van der Lee R, de Groot NS, et al. Intrinsically disordered proteins: regulation and disease. Curr Opin Struc Biol. 2011;21(3):432–440.

•Overview about the importance of IDPs for signaling fidelity and drug targeting.

  • Vendruscolo M. Enzymatic activity in disordered states of proteins. Curr Opin Chem Biol. 2010;14(5):671–675.
  • Schulenburg C, Hilvert D. Protein conformational disorder and enzyme catalysis. Top Curr Chem. 2013;337:41–67.
  • Smock RG, Blackburn ME, Gierasch LM. Conserved, disordered C terminus of DnaK enhances cellular survival upon stress and DnaK in vitro chaperone activity. J Biol Chem. 2011;286(36):31821–31829.
  • Tompa P, Csermely P. The role of structural disorder in the function of RNA and protein chaperones. FASEB J. 2004;18(11):1169–1175.
  • Kuznetsova IM, Turoverov KK, Uversky VN. What macromolecular crowding can do to a protein. Int J Mol Sci. 2014;15(12):23090–23140.
  • Greenwald J, Riek R. Biology of amyloid: structure, function, and regulation. Structure. 2010;18(10):1244–1260.
  • Nag S, Sarkar B, Bandyopadhyay A, et al. Nature of the amyloid-beta monomer and the monomer-oligomer equilibrium. J Biol Chem. 2011;286(16):13827–13833.
  • Chakrabortee S, Meersman F, Kaminski Schierle GS, et al. Catalytic and chaperone-like functions in an intrinsically disordered protein associated with desiccation tolerance. Proc Natl Acad Sci USA. 2010;107(37):16084–16089.
  • Uversky VN. Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Expert Rev Proteomics. 2010;7(4):543–564.
  • Midic U, Oldfield CJ, Dunker AK, et al. Protein disorder in the human diseasome: unfoldomics of human genetic diseases. BMC Genomics. 2009;10(Suppl 1):S12.
  • Uversky VN, Oldfield CJ, Midic U, et al. Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics. 2009;10(Suppl 1):S7.
  • Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475(7356):324–332.
  • Lee L, Sakurai M, Matsuzaki S, et al. SUMO and Alzheimer’s disease. NeuroMolecular Med. 2013;15(4):720–736.
  • Uversky VN. Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci. 2014;1:6.
  • Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862–873.
  • Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–317.
  • Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010;17(6):901–911.
  • Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell. 2003;112(2):193–205.
  • Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1–11.
  • Hammoudeh DI, Follis AV, Prochownik EV, et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009;131(21):7390–7401.
  • Cheng Y, LeGall T, Oldfield CJ, et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 2006;24(10):435–442.
  • Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res. 1971;14:295–358.
  • Cooper GJ, Leighton B, Dimitriadis GD, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA. 1988;85(20):7763–7766.
  • Cheng Y, LeGall T, Oldfield CJ, et al. Abundance of intrinsic disorder in protein associated with cardiovascular disease. Biochemistry. 2006;45(35):10448–10460.
  • Derisbourg M, Leghay C, Chiappetta G, et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep. 2015;5:9659.
  • Chen J, Kanai Y, Cowan NJ, et al. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature. 1992;360(6405):674–677.
  • Kadavath H, Hofele RV, Biernat J, et al. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci USA. 2015;112(24):7501–7506.
  • Kadavath H, Jaremko M, Jaremko L, et al. Folding of the Tau protein on microtubules. Angew Chem. 2015;54(35):10347–10351.

••Study demonstrating the folding of specific regions in microtubule associated protein Tau upon binding to mega-Dalton sized microtubules.

  • Sergeant N, Bretteville A, Hamdane M, et al. Biochemistry of Tau in Alzheimer’s disease and related neurological disorders. Expert Rev Proteomics. 2008;5(2):207–224.
  • Mandelkow EM, Biernat J, Drewes G, et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging. 1995;16(3):355–362; discussion 62–3
  • Cripps D, Thomas SN, Jeng Y, et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem. 2006;281(16):10825–10838.
  • Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.
  • Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33(1):95–130.
  • Tepper K, Biernat J, Kumar S, et al. Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem. 2014;289(49):34389–34407.
  • Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, et al. Tau oligomers as potential targets for immunotherapy for Alzheimer’s disease and tauopathies. Curr Alzheimer Res. 2011;8(6):659–665.
  • Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159.

••Comprehensive review on the role of protein Tau in neurodegenerative diseases.

  • Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci. 2013;14(9):626–636.
  • Akoury E, Gajda M, Pickhardt M, et al. Inhibition of tau filament formation by conformational modulation. J Am Chem Soc. 2013;135(7):2853–2862.
  • Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102(19):6990–6995.
  • Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA. 2005;102(1):227–231.
  • Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimer’s disease. Expert Opin Biol Ther. 2011;11(3):343–357.
  • Davidson WS, Jonas A, Clayton DF, et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273(16):9443–9449.
  • Auluck PK, Caraveo G, Lindquist S. alpha-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol. 2010;26:211–233.
  • Goedert M, Spillantini MG, Del Tredici K, et al. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13–24.
  • Jimenez JL, Guijarro JI, Orlova E, et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 1999;18(4):815–821.
  • Wegmann S, Muller DJ, Mandelkow E. Investigating fibrillar aggregates of Tau protein by atomic force microscopy. Methods Mol Biol. 2012;849:169–183.
  • Gibbs EB, Showalter SA. Quantitative biophysical characterization of intrinsically disordered proteins. Biochemistry. 2015;54(6):1314–1326.
  • Galea CA, Nourse A, Wang Y, et al. Role of intrinsic flexibility in signal transduction mediated by the cell cycle regulator, p27 Kip1. J Mol Biol. 2008;376(3):827–838.
  • Ferreon AC, Moran CR, Gambin Y, et al. Single-molecule fluorescence studies of intrinsically disordered proteins. Methods Enzymol. 2010;472:179–204.
  • Ferreon AC, Moosa MM, Gambin Y, et al. Counteracting chemical chaperone effects on the single-molecule alpha-synuclein structural landscape. Proc Natl Acad Sci USA. 2012;109(44):17826–17831.
  • Krishnan R, Goodman JL, Mukhopadhyay S, et al. Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proc Natl Acad Sci USA. 2012;109(28):11172–11177.
  • Ferreon AC, Ferreon JC, Wright PE, et al. Modulation of allostery by protein intrinsic disorder. Nature. 2013;498(7454):390–394.
  • Lee T, Moran-Gutierrez CR, Deniz AA. Probing protein disorder and complexity at single-molecule resolution. Semin Cell Dev Biol. 2015;37:26–34.
  • Ferreon AC, Gambin Y, Lemke EA, et al. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci USA. 2009;106(14):5645–5650.
  • Ferreon AC, Moran CR, Ferreon JC, et al. Alteration of the alpha-synuclein folding landscape by a mutation related to Parkinson’s disease. Angew Chem. 2010;49(20):3469–3472.
  • Aznauryan M, Nettels D, Holla A, et al. Single-molecule spectroscopy of cold denaturation and the temperature-induced collapse of unfolded proteins. J Am Chem Sci. 2013;135(38):14040–14043.
  • Brucale M, Schuler B, Samori B. Single-molecule studies of intrinsically disordered proteins. Chem Rev. 2014;114(6):3281–3317.
  • Soranno A, Koenig I, Borgia MB, et al. Single-molecule spectroscopy reveals polymer effects of disordered proteins in crowded environments. Proc Natl Acad Sci USA. 2014;111(13):4874–4879.
  • Wuttke R, Hofmann H, Nettels D, et al. Temperature-dependent solvation modulates the dimensions of disordered proteins. Proc Natl Acad Sci USA. 2014;111(14):5213–5218.
  • Konig I, Zarrine-Afsar A, Aznauryan M, et al. Single-molecule spectroscopy of protein conformational dynamics in live eukaryotic cells. Nat Methods. 2015;12(8):773–779.
  • Bernado P, Svergun DI. Structural analysis of intrinsically disordered proteins by small-angle X-ray scattering. Mol Biosyst. 2012;8(1):151–167.
  • Narayanan RL, Durr UH, Bibow S, et al. Automatic assignment of the intrinsically disordered protein Tau with 441-residues. J Am Chem Sci. 2010;132(34):11906–11907.
  • Felli IC, Pierattelli R. Recent progress in NMR spectroscopy: toward the study of intrinsically disordered proteins of increasing size and complexity. IUBMB Life. 2012;64(6):473–481.

•Detailed description of advances in NMR spectroscopy for IDP characterization.

  • Konrat R. NMR contributions to structural dynamics studies of intrinsically disordered proteins. J Magn Reson. 2014;241:74–85.
  • Yao X, Becker S, Zweckstetter M. A six-dimensional alpha proton detection-based APSY experiment for backbone assignment of intrinsically disordered proteins. J Biomol NMR. 2014;60(4):231–240.
  • Wishart DS, Sykes BD. The 13C chemical-shift index: a simple method for the identification of protein secondary structure using 13C chemical-shift data. J Biomol NMR. 1994;4(2):171–180.
  • Mittag T, Forman-Kay JD. Atomic-level characterization of disordered protein ensembles. Curr Opin Struc Biol. 2007;17(1):3–14.

•Description of experimental and computational methods for IDP ensemble description.

  • Jensen MR, Markwick PR, Meier S, et al. Quantitative determination of the conformational properties of partially folded and intrinsically disordered proteins using NMR dipolar couplings. Structure. 2009;17(9):1169–1185.
  • Kosol S, Contreras-Martos S, Cedeno C, et al. Structural characterization of intrinsically disordered proteins by NMR spectroscopy. Molecules. 2013;18(9):10802–10828.
  • Schwalbe M, Kadavath H, Biernat J, et al. Structural impact of Tau phosphorylation at threonine 231. Structure. 2015;23(8):1448–1458.
  • Salmon L, Nodet G, Ozenne V, et al. NMR characterization of long-range order in intrinsically disordered proteins. J Am Chem Sci. 2010;132(24):8407–8418.
  • Bertoncini CW, Jung YS, Fernandez CO, et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci. 2005;102(5):1430–1435.

••Study revealing critical changes in conformational ensemble of alpha-synuclein, the protein which folds into pathogenic aggregates in Parkinson disease.

  • Dedmon MM, Lindorff-Larsen K, Christodoulou J, et al. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Sci. 2005;127(2):476–477.
  • Schwalbe M, Ozenne V, Bibow S, et al. Predictive atomic resolution descriptions of intrinsically disordered hTau40 and alpha-synuclein in solution from NMR and small angle scattering. Structure. 2014;22(2):238–249.
  • Mukrasch MD, Bibow S, Korukottu J, et al. Structural polymorphism of 441-residue tau at single residue resolution. PloS Biology. 2009;7(2):e34.

•Study reporting an ensemble description of the full-length Tau protein and its interactions with microtubules.

  • Palmer AG, Massi F. Characterization of the dynamics of biomacromolecules using rotating-frame spin relaxation NMR spectroscopy. Chem Rev. 2006;106(5):1700–1719.
  • Korzhnev DM, Kay LE. Probing invisible, low-populated states of protein molecules by relaxation dispersion NMR spectroscopy: an application to protein folding. Acc Chem Res. 2008;41(3):442–451.
  • Allison JR, Varnai P, Dobson CM, et al. Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. J Am Chem Sci. 2009;131(51):18314–18326.
  • Xiang S, Gapsys V, Kim HY, et al. Phosphorylation drives a dynamic switch in serine/arginine-rich proteins. Structure. 2013;21(12):2162–2174.

•Atomic level study of phosphorylation induced dynamic switch in an IDP.

  • Lindorff-Larsen K, Trbovic N, Maragakis P, et al. Structure and dynamics of an unfolded protein examined by molecular dynamics simulation. J Am Chem Sci. 2012;134(8):3787–3791.
  • Piana S, Klepeis JL, Shaw DE. Assessing the accuracy of physical models used in protein-folding simulations: quantitative evidence from long molecular dynamics simulations. Curr Opin Struc Biol. 2014;24:98–105.

•Assessment of molecular dynamic simulations for the study of IDPs.

  • Patel S, Ramanujam V, Srivastava AK, et al. Conformational propensities and dynamics of a betagamma-crystallin, an intrinsically disordered protein. Phys Chem Chem Phys. 2014;16(25):12703–12718.
  • Rezaei-Ghaleh N, Klama F, Munari F, et al. Predicting the rotational tumbling of dynamic multidomain proteins and supramolecular complexes. Angew Chem. 2013;52(43):11410–11414.
  • Rezaei-Ghaleh N, Klama F, Munari F, et al. HYCUD: a computational tool for prediction of effective rotational correlation time in flexible proteins. Bioinformatics. 2015;31(8):1319–1321.
  • Metallo SJ. Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol. 2010;14(4):481–488.
  • Follis AV, Hammoudeh DI, Wang H, et al. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008;15(11):1149–1155.
  • Cuchillo R, Michel J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem Soc Trans. 2012;40(5):1004–1008.
  • Michel J, Cuchillo R. The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc. PloS One. 2012;7(7):e41070.
  • Jin F, Yu C, Lai L, et al. Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins. PLoS Comput Biol. 2013;9(10):e1003249.
  • Krishnan N, Koveal D, Miller DH, et al. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol. 2014;10(7):558–566.
  • Heller GT, Sormanni P, Vendruscolo M. Targeting disordered proteins with small molecules using entropy. Trends Biochem Sci. 2015;40(9):491–496.
  • Fonseca-Ornelas L, Eisbach SE, Paulat M, et al. Small molecule-mediated stabilization of vesicle-associated helical alpha-synuclein inhibits pathogenic misfolding and aggregation. Nat Comm. 2014;5:5857.

•Study describing a novel strategy for inhibition of the pathogenic aggregation of vesical bound alpha-synuclein.

  • Jung KY, Wang H, Teriete P, et al. Perturbation of the c-Myc-Max protein-protein interaction via synthetic alpha-helix mimetics. J Med Chem. 2015;58(7):3002–3024.
  • Schirmer RH, Adler H, Pickhardt M, et al. Lest we forget you–methylene blue. Neurobiol Aging. 2011;32(12):2325, e7–16.
  • Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2015;44(2):705–720.
  • Akoury E, Pickhardt M, Gajda M, et al. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew Chem. 2013;52(12):3511–3515.

•NMR-based study elucidating the mechanism of small molecule-mediated inhibition of Tau aggregation.

  • Toth G, Gardai SJ, Zago W, et al. Targeting the intrinsically disordered structural ensemble of alpha-synuclein by small molecules as a potential therapeutic strategy for Parkinson’s disease. PloS One. 2014;9(2):e87133.

•First report on directly targeting IDP ensembles for drug discovery.

  • Weinreb PH, Zhen W, Poon AW, et al. NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry. 1996;35(43):13709–13715.
  • Acharya S, Safaie BM, Wongkongkathep P, et al. Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer. J Biol Chem. 2014;289(15):10727–10737.
  • Prabhudesai S, Sinha S, Attar A, et al. A novel “molecular tweezer” inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics. 2012;9(2):464–476.
  • Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702–716.
  • Chene P. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res. 2004;2(1):20–28.
  • Khoo KH, Verma CS, Lane DP;. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13(3):217–236.
  • Yin X, Giap C, Lazo JS, et al. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003;22(40):6151–6159.
  • Aeluri M, Chamakuri S, Dasari B, et al. Small molecule modulators of protein-protein interactions: selected case studies. Chem Rev. 2014;114(9):4640–4694.
  • Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015;145:76–84.
  • Besbes S, Mirshahi M, Pocard M, et al. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget. 2015;6(15):12862–12871.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.